Authors
Latest:
Can New Protocols Reduce Costs of Multiple Myeloma Treatment?Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.
Latest:
Brain Benefits: Targeted Therapy Offers New Weapon Against HER2+ Breast Cancer with LMMina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.
Latest:
Convenient Saliva Test Could Predict Head and Neck Cancer RecurrenceElizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.
Latest:
Promising New Therapy for Hematologic Malignancies in Young PatientsAlice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.
Latest:
Unmet Needs in R/R MM and Clinical Practice PearlsClosing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
Latest:
Looking Ahead for Melanoma TreatmentJose Lutzky, MD, discusses clinical trials investigating novel therapies for melanoma.
Latest:
Recent Trial Updates in Advanced Renal Cell Carcinoma (RCC)In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.
Latest:
Unmet Needs and Clinical Pearls for Treating Relapsed/Refractory CLLCatherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Understanding Adjuvant Therapy in Bladder CancerAlex Chehrazi-Raffle, MD, discusses findings from a real-world analysis of adjuvant treatment in bladder cancer presented at ASCO GU.
Latest:
Addressing Unmet Needs in SCLCMissak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.
Latest:
Adagrasib Demonstrates Superiority in KRAS G12C NSCLCRobert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated NSCLC.
Latest:
Obesity May Increase Chronic GVHD After Stem Cell TransplantValentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.
Latest:
Molecular Testing Used for Patients With Non-Small Cell Lung CancerRogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.
Latest:
Exploring the Reasons Why Certain Prostate Cancers Are More AggressivePaul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
The Role of Targeted Therapies in Frontline Treatment of Mantle Cell LymphomaThere have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.
Latest:
Factors Influencing Frontline Therapy Options for Favorable-Risk RCCNaomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.
Latest:
Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALLDespite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.
Latest:
Varying Incidence of HPV-Positive and Negative Oropharyngeal CancersJimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.
Latest:
Multiple Factors at Play in the Rise of Early-Onset Colorectal CancerOncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for TreatmentEnrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
Latest:
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Latest:
Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLCAntitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.
Latest:
Combined Risk Factors Lead to Worse Outcomes in Colon CancerLuv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.
Latest:
Unmet Needs in Oligometastatic Prostate CancerChad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.
Latest:
Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat NETs Requires Real-World GuideA real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.
Latest:
Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCCFor patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.
